FACEBOOK  |  TWITTER  |  INSTAGRAM  |  LINKEDIN  |  Contact Us  |  Site Map
Get Involved

John F. Engelhardt, PhD

John F. Engelhardt, PhD
University of Iowa

What is your current professional status?


What is your work setting (i.e. academic institution, government organization (i.e. FDA, NIH, etc.), bio-industry/pharmaceutical company, etc.)

Academic Institution

What is your scientific area of research?

Cystic Fibrosis and gene therapy.

Why do you want to be a mentor?

To help the next generation of scientists.

As a mentor, what are you hoping to gain from this experience?

To learn how to be a better mentor.           

How important are the following in the selection of a mentee: (1 – 5 scale, 1 = most important, 5 = least important)

            a. Compatibility of Scientific Specialties - 2
            b. Geographic Location - 3
            c. Professional Status / Success - 2
            d. Compatibility of Career Path - 2
            e. Communication Style - 2

Summarized in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy.

John F. Engelhardt is the Director of the Center for Gene Therapy, Professor and Head of the Department of Anatomy and Cell Biology, and Professor in the Department of Internal Medicine at the University of Iowa Roy J. and Lucille A. Carver College of Medicine. He currently holds the Roy J. Carver Chair of Molecular Medicine and has been Director of the Center for Gene Therapy at the University of Iowa for the past 16 years. He received his undergraduate degree in biochemistry from Iowa State University in 1985, and his doctorate in human genetics from Johns Hopkins University in 1990. Research in the Engelhardt laboratory focuses on the following areas: 1) the study of the molecular and cellular pathogenesis of cystic fibrosis (CF) lung disease and diabetes, 2) molecular mechanisms of redox-mediated signal transduction in response to pro-inflammatory signals, 3) the study of airway stem cells and submucosal gland development, 4) the development of animal models for CF lung disease with a focus on the ferret, and 5) the development of gene therapies for CF with a focus on recombinant adeno-associated virus and its transduction biology.

Click here to view John Engelhardt's CV.